Literature DB >> 11276204

Extracellular matrix interacts with soluble CD95L: retention and enhancement of cytotoxicity.

K Aoki1, M Kurooka, J J Chen, J Petryniak, E G Nabel, G J Nabel.   

Abstract

Fas ligand (CD95L) is synthesized both on the cell surface membrane and in a soluble form. Although CD95L contributes to immune privilege in the cornea and testis, the functions of these alternatively processed proteins are not well understood. Some reports suggest that the cytotoxicity of soluble CD95L is insignificant, whereas others show potent responses in vivo, including hepatocyte apoptosis that causes liver failure. We show here that extracellular matrix proteins interact with soluble CD95L and potentiate its pro-apoptotic activity. The cytotoxicity of supernatants from CD95L-expressing cells was increased by incubation on tissue culture plates coated with these matrix proteins; this effect was mediated by trimeric soluble CD95L. With the use of immunoprecipitation, it was found that CD95L binds directly to fibronectin. In addition, immunohistochemical analysis of the cornea revealed that soluble CD95L binds primarily to extracellular matrix. The retention of soluble CD95L on extracellular matrices is likely to play an important role in the development of peripheral tolerance in immune-privileged sites.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11276204     DOI: 10.1038/86336

Source DB:  PubMed          Journal:  Nat Immunol        ISSN: 1529-2908            Impact factor:   25.606


  22 in total

Review 1.  FLICE-inhibitory proteins: regulators of death receptor-mediated apoptosis.

Authors:  A Krueger; S Baumann; P H Krammer; S Kirchhoff
Journal:  Mol Cell Biol       Date:  2001-12       Impact factor: 4.272

2.  CD95 and CD95L promote and protect cancer stem cells.

Authors:  Paolo Ceppi; Abbas Hadji; Frederick J Kohlhapp; Abhinandan Pattanayak; Annika Hau; Xia Liu; Huiping Liu; Andrea E Murmann; Marcus E Peter
Journal:  Nat Commun       Date:  2014-11-04       Impact factor: 14.919

3.  Signaling active CD95 receptor molecules trigger co-translocation of inactive CD95 molecules into lipid rafts.

Authors:  Isabell Lang; Andrea Fick; Viktoria Schäfer; Tina Giner; Daniela Siegmund; Harald Wajant
Journal:  J Biol Chem       Date:  2012-05-29       Impact factor: 5.157

Review 4.  The Tumor Necrosis Factor Family: Family Conventions and Private Idiosyncrasies.

Authors:  David Wallach
Journal:  Cold Spring Harb Perspect Biol       Date:  2018-10-01       Impact factor: 10.005

5.  The contribution of the Fas/FasL apoptotic pathway in ulcer formation during Leishmania major-induced cutaneous Leishmaniasis.

Authors:  Liv Eidsmo; Susanne Nylen; Ali Khamesipour; Mari-Anne Hedblad; Francesca Chiodi; Hannah Akuffo
Journal:  Am J Pathol       Date:  2005-04       Impact factor: 4.307

6.  Induction of stress response renders human tumor cell lines resistant to curcumin-mediated apoptosis: role of reactive oxygen intermediates.

Authors:  A Khar; A M Ali; B V Pardhasaradhi; C H Varalakshmi; R Anjum; A L Kumari
Journal:  Cell Stress Chaperones       Date:  2001-10       Impact factor: 3.667

7.  A Fas Ligand (FasL)-Fused Humanized Antibody Against Tumor-Associated Glycoprotein 72 Selectively Exhibits the Cytotoxic Effect Against Oral Cancer Cells with a Low FasL/Fas Ratio.

Authors:  Ming-Hsien Chien; Wei-Min Chang; Wei-Jiunn Lee; Yu-Chan Chang; Tsung-Ching Lai; Derek V Chan; Rahul Sharma; Yuan-Feng Lin; Michael Hsiao
Journal:  Mol Cancer Ther       Date:  2017-03-14       Impact factor: 6.261

8.  Death induced by CD95 or CD95 ligand elimination.

Authors:  Abbas Hadji; Paolo Ceppi; Andrea E Murmann; Sonia Brockway; Abhinandan Pattanayak; Bhavneet Bhinder; Annika Hau; Shirley De Chant; Vamsi Parimi; Piotre Kolesza; Joanne Richards; Navdeep Chandel; Hakim Djaballah; Marcus E Peter
Journal:  Cell Rep       Date:  2014-03-20       Impact factor: 9.423

9.  CD95 ligand induces motility and invasiveness of apoptosis-resistant tumor cells.

Authors:  Bryan C Barnhart; Patrick Legembre; Eric Pietras; Concetta Bubici; Guido Franzoso; Marcus E Peter
Journal:  EMBO J       Date:  2004-07-22       Impact factor: 11.598

10.  Two CD95 tumor classes with different sensitivities to antitumor drugs.

Authors:  Alicia Algeciras-Schimnich; Eric M Pietras; Bryan C Barnhart; Patrick Legembre; Shrijay Vijayan; Susan L Holbeck; Marcus E Peter
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-22       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.